NO324276B1 - Vandige insulinpreparater som inneholder mannitol. - Google Patents

Vandige insulinpreparater som inneholder mannitol. Download PDF

Info

Publication number: NO324276B1
Authority: NO; Norway
Prior art keywords: insulin; solution; preparation; added; human insulin
Prior art date: 1996-06-20

Application number

NO19985978A

Other languages

English (en)

Norwegian (no)

Other versions

NO985978D0 (no

NO985978L (no

Inventor

Per Balschmidt

Lone Logstrup Kimer

Steen Jensen

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-20

Filing date

1998-12-18

Publication date

2007-09-17

1998-12-18 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

1998-12-18 Publication of NO985978D0 publication Critical patent/NO985978D0/no

1999-02-19 Publication of NO985978L publication Critical patent/NO985978L/no

2007-09-17 Publication of NO324276B1 publication Critical patent/NO324276B1/no

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 193
102000004877 Insulin Human genes 0.000 title claims abstract description 81
108090001061 Insulin Proteins 0.000 title claims abstract description 81
229940125396 insulin Drugs 0.000 title claims abstract description 81
238000002360 preparation method Methods 0.000 title claims abstract description 81
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 title claims description 22
229930195725 Mannitol Natural products 0.000 title claims description 22
239000000594 mannitol Substances 0.000 title claims description 22
235000010355 mannitol Nutrition 0.000 title claims description 22
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims abstract description 49
101000976075 Homo sapiens Insulin Proteins 0.000 claims abstract description 41
108010007568 Protamines Proteins 0.000 claims description 27
102000007327 Protamines Human genes 0.000 claims description 27
239000004026 insulin derivative Substances 0.000 claims description 23
229940048914 protamine Drugs 0.000 claims description 21
239000013078 crystal Substances 0.000 claims description 18
239000011701 zinc Substances 0.000 claims description 15
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 13
229910052725 zinc Inorganic materials 0.000 claims description 13
150000002989 phenols Chemical class 0.000 claims description 8
239000000872 buffer Substances 0.000 claims description 4
239000008363 phosphate buffer Substances 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
239000000203 mixture Substances 0.000 abstract description 14
150000001720 carbohydrates Chemical class 0.000 abstract description 6
125000004432 carbon atom Chemical group C* 0.000 abstract 2
150000002148 esters Chemical class 0.000 abstract 1
150000002170 ethers Chemical class 0.000 abstract 1
239000000243 solution Substances 0.000 description 97
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 40
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
238000002156 mixing Methods 0.000 description 26
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 20
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
239000000725 suspension Substances 0.000 description 15
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 14
150000001413 amino acids Chemical class 0.000 description 10
102000005237 Isophane Insulin Human genes 0.000 description 9
108010081368 Isophane Insulin Proteins 0.000 description 9
206010012601 diabetes mellitus Diseases 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
229950008679 protamine sulfate Drugs 0.000 description 8
KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 7
235000005074 zinc chloride Nutrition 0.000 description 7
239000011592 zinc chloride Substances 0.000 description 7
238000002425 crystallisation Methods 0.000 description 5
230000008025 crystallization Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
101001011741 Bos taurus Insulin Proteins 0.000 description 3
239000003929 acidic solution Substances 0.000 description 3
239000012670 alkaline solution Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 3
LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 3
239000007951 isotonicity adjuster Substances 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
229940075562 sodium phosphate dihydrate Drugs 0.000 description 3
CRKADHVTAQCXRA-UHFFFAOYSA-K trisodium;phosphate;dihydrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]P([O-])([O-])=O CRKADHVTAQCXRA-UHFFFAOYSA-K 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
241001202975 Isophanes Species 0.000 description 2
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
238000013019 agitation Methods 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
206010061592 cardiac fibrillation Diseases 0.000 description 2
RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 2
230000002600 fibrillogenic effect Effects 0.000 description 2
239000012467 final product Substances 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
229940006445 isophane insulin Drugs 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
150000003751 zinc Chemical class 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108010005991 Pork Regular Insulin Proteins 0.000 description 1
241000201776 Steno Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
101000993800 Sus scrofa Insulin Proteins 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
239000012928 buffer substance Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000010276 construction Methods 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
238000000151 deposition Methods 0.000 description 1
201000010064 diabetes insipidus Diseases 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000016097 disease of metabolism Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
GQUCWSONMNQDRA-UHFFFAOYSA-L disodium;[hydroxy(oxido)phosphoryl] hydrogen phosphate;dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GQUCWSONMNQDRA-UHFFFAOYSA-L 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
108010066090 neutral insulin Proteins 0.000 description 1
239000002245 particle Substances 0.000 description 1
-1 phenol compound Chemical class 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000036325 urinary excretion Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Zoology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

NO19985978A 1996-06-20 1998-12-18 Vandige insulinpreparater som inneholder mannitol. NO324276B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DK68496		1996-06-20
DK89996		1996-08-27
PCT/DK1997/000267 WO1997048413A1 (en)	1996-06-20	1997-06-19	Insulin preparations containing carbohydrates

Publications (3)

Publication Number	Publication Date
NO985978D0 NO985978D0 (no)	1998-12-18
NO985978L NO985978L (no)	1999-02-19
NO324276B1 true NO324276B1 (no)	2007-09-17

Family

ID=26064448

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19985978A NO324276B1 (no)	1996-06-20	1998-12-18	Vandige insulinpreparater som inneholder mannitol.

Country Status (16)

Country	Link
EP (1)	EP0910402B1 (de)
JP (2)	JP4472027B2 (de)
KR (1)	KR20000022030A (de)
CN (1)	CN1198643C (de)
AT (1)	ATE369146T1 (de)
AU (1)	AU719361B2 (de)
BR (1)	BR9709844A (de)
CA (1)	CA2258099A1 (de)
CZ (1)	CZ297682B6 (de)
DE (1)	DE69737995T2 (de)
ES (1)	ES2292189T3 (de)
HU (1)	HUP9904156A3 (de)
IL (1)	IL127365A0 (de)
NO (1)	NO324276B1 (de)
PL (1)	PL188736B1 (de)
WO (1)	WO1997048413A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA989644B (en) *	1997-10-24	2000-04-25	Lilly Co Eli	Insoluble insulen compositions.
AR020047A1 (es)	1997-10-24	2002-04-10	Lilly Co Eli	Composiciones insolubles de insulina, formulaciones en suspension que incluyen dicha composicion insoluble de insulina; y el uso de dicha composicionpara preparar medicamentos y procedimiento para preparar dichas composiciones insolubles.
EP1396272A1 (de) *	1997-12-23	2004-03-10	Eli Lilly & Company	Unlöslische Insulin Zusammensetzungen zur Regelung der Blutglukose
CO4970787A1 (es)	1997-12-23	2000-11-07	Lilly Co Eli	Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
AU2827199A (en) *	1998-03-24	1999-10-18	Klavs Holger Jorgensen	Novel preparation of protracted acting human insulin
GB9806462D0 (en) *	1998-03-26	1998-05-27	Glaxo Group Ltd	Improved compositions for inhalation
US6211144B1 (en)	1998-10-16	2001-04-03	Novo Nordisk A/S	Stable concentrated insulin preparations for pulmonary delivery
AU758146B2 (en) *	1998-10-16	2003-03-13	Novo Nordisk A/S	Stable concentrated insulin preparations for pulmonary delivery
HUP0103606A3 (en) *	1998-10-16	2002-05-28	Novo Nordisk As	Insulin preparations for pulmonary delivery containing menthol
US6635617B1 (en)	1998-10-16	2003-10-21	Novo Nordisk A/S	Insulin preparations for pulmonary delivery containing menthol
JP4567668B2 (ja) *	2003-05-01	2010-10-20	株式会社Ｌｔｔバイオファーマ	亜鉛含有徐放性組成物，その製剤およびその製造方法
LT2918286T (lt) *	2004-10-05	2020-04-10	Novo Nordisk A/S	Farmacinis preparatas, kurio sudėtyje yra kristalinės ir taip pat ištirpintos formos insulino
US8263551B2 (en)	2004-11-22	2012-09-11	Novo Nordisk A/S	Soluble, stable insulin-containing formulations with a protamine salt
CN1931360B (zh) *	2006-09-22	2013-02-13	江苏万邦生化医药股份有限公司	双时相精蛋白锌胰岛素注射液(30%)及其制备方法
CA2711749A1 (en)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Novel insulin derivatives having an extremely delayed time-action profile
RS59913B1 (sr)	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
SG10201403840VA (en)	2009-07-06	2014-10-30	Sanofi Aventis Deutschland	Aqueous insulin preparations containing methionine
SI2498802T1 (sl)	2009-11-13	2015-05-29	Sanofi-Aventis Deutschland Gmbh	Farmacevtski sestavek, ki vsebuje agonist GLP-1, inzulin in metionin
PL2498801T3 (pl)	2009-11-13	2018-08-31	Sanofi Aventis Deutschland	Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę
BR112013004756B1 (pt)	2010-08-30	2020-04-28	Sanofi Aventis Deutschland	uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CA2846413C (en)	2011-08-29	2021-11-02	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI641381B (zh)	2013-02-04	2018-11-21	法商賽諾菲公司	胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
CA2932877A1 (en) *	2014-01-09	2015-07-16	Sanofi	Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP7173953B2 (ja) *	2014-01-09	2022-11-16	サノフイ	インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
JP2020143105A (ja) *	2014-01-09	2020-09-10	サノフイＳａｎｏｆｉ	インスリンアスパルトの安定化された医薬製剤
JP2020114861A (ja) *	2014-01-09	2020-07-30	サノフイＳａｎｏｆｉ	インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
RU2016132340A (ru) *	2014-01-09	2018-02-14	Санофи	Стабилизированные фармацевтические составы на основе инсулина аспарта
EP3091965A1 (de)	2014-01-09	2016-11-16	Sanofi	Stabilisierte glycerinfreie pharmazeutische formulierungen von insulinanaloga und/oder insulinderivaten
TWI758239B (zh)	2014-12-12	2022-03-21	德商賽諾菲阿凡提斯德意志有限公司	甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
WO2017163159A1 (en) *	2016-03-21	2017-09-28	Wockhardt Limited	Biphasic pharmaceutical composition of insulin human

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4439181A (en) *	1981-01-26	1984-03-27	Regents Of The University Of Minnesota	Polyol-hormone mixture for use in chronic parenteral hormone administration
US4839341A (en) *	1984-05-29	1989-06-13	Eli Lilly And Company	Stabilized insulin formulations
US4876241A (en) *	1987-05-22	1989-10-24	Armour Pharmaceutical Company	Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
DE122006000017I1 (de) *	1993-06-21	2006-06-29	Novo Nordisk As	ASP-B28-Insulinkristalle

1997
- 1997-06-19 PL PL97330828A patent/PL188736B1/pl not_active IP Right Cessation
- 1997-06-19 ES ES97927018T patent/ES2292189T3/es not_active Expired - Lifetime
- 1997-06-19 JP JP50212898A patent/JP4472027B2/ja not_active Expired - Lifetime
- 1997-06-19 AT AT97927018T patent/ATE369146T1/de not_active IP Right Cessation
- 1997-06-19 AU AU31665/97A patent/AU719361B2/en not_active Ceased
- 1997-06-19 KR KR1019980710428A patent/KR20000022030A/ko not_active Ceased
- 1997-06-19 BR BR9709844A patent/BR9709844A/pt not_active IP Right Cessation
- 1997-06-19 CA CA002258099A patent/CA2258099A1/en not_active Abandoned
- 1997-06-19 CZ CZ0395798A patent/CZ297682B6/cs not_active IP Right Cessation
- 1997-06-19 EP EP97927018A patent/EP0910402B1/de not_active Expired - Lifetime
- 1997-06-19 DE DE69737995T patent/DE69737995T2/de not_active Expired - Lifetime
- 1997-06-19 HU HU9904156A patent/HUP9904156A3/hu unknown
- 1997-06-19 WO PCT/DK1997/000267 patent/WO1997048413A1/en not_active Ceased
- 1997-06-19 IL IL12736597A patent/IL127365A0/xx active IP Right Grant
- 1997-06-19 CN CNB971956642A patent/CN1198643C/zh not_active Expired - Fee Related
1998
- 1998-12-18 NO NO19985978A patent/NO324276B1/no unknown
2009
- 2009-05-07 JP JP2009112968A patent/JP2009242400A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
PL330828A1 (en)	1999-06-07
PL188736B1 (pl)	2005-04-29
CZ395798A3 (cs)	1999-05-12
EP0910402B1 (de)	2007-08-08
CN1198643C (zh)	2005-04-27
IL127365A0 (en)	1999-10-28
JP2000513343A (ja)	2000-10-10
NO985978D0 (no)	1998-12-18
ES2292189T3 (es)	2008-03-01
WO1997048413A1 (en)	1997-12-24
AU719361B2 (en)	2000-05-04
NO985978L (no)	1999-02-19
CA2258099A1 (en)	1997-12-24
ATE369146T1 (de)	2007-08-15
JP2009242400A (ja)	2009-10-22
DE69737995T2 (de)	2008-04-24
EP0910402A1 (de)	1999-04-28
AU3166597A (en)	1998-01-07
HUP9904156A3 (en)	2000-07-28
JP4472027B2 (ja)	2010-06-02
HUP9904156A2 (hu)	2000-06-28
DE69737995D1 (de)	2007-09-20
CN1222084A (zh)	1999-07-07
CZ297682B6 (cs)	2007-03-07
KR20000022030A (ko)	2000-04-25
BR9709844A (pt)	1999-08-10

Publication	Publication Date	Title
NO324276B1 (no)	2007-09-17	Vandige insulinpreparater som inneholder mannitol.
US5948751A (en)	1999-09-07	X14-mannitol
US5866538A (en)	1999-02-02	Insulin preparations containing NaCl
US5834422A (en)	1998-11-10	AspB28 insulin compositions
EP0921812B1 (de)	2001-11-07	Halogenid-enthaltende insulinzubereitungen
EP0705275B1 (de)	1999-02-03	Asp-b28-insulinkristalle
DK176213B1 (da)	2007-02-12	Insulinanalog-protamin-komplekser, parenterale formuleringer indeholdende disse samt fremgangsmåde til fremstilling af LysB28ProB29-human insulin-protaminkrystaller og fremgangsmåde til fremstilling af insulin-protamin-komplekser og -krystaller
WO2010028055A1 (en)	2010-03-11	Insulin with a basal release profile
HRP20000427A2 (en)	2001-06-30	Insoluble compositions for controlling blood glucose
RU2204411C2 (ru)	2003-05-20	Инсулиновые препараты, содержащие углеводы
RU2154494C2 (ru)	2000-08-20	Комплекс аналога инсулина и протамина, способ получения, фармацевтическая композиция и способ лечения диабета
IL127365A (en)	2006-12-10	Insulin preparations containing carbohydrates
MXPA98010515A (en)	1999-10-14	Insulin preparations containing so chloride